Medicus Pharma Ltd. (MDCX.V)
| Previous Close | 3.7000 |
| Open | 3.7000 |
| Bid | 3.2300 x N/A |
| Ask | 3.2900 x N/A |
| Day's Range | 3.2200 - 3.7000 |
| 52 Week Range | 0.3100 - 3.8000 |
| Volume | |
| Avg. Volume | 2,636 |
| Market Cap | 70.504M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Medicus Pharma Ltd. Announces First Patient Randomized in Phase 2 Trial of SKNJCT-003 for the Treatment of Nodular Basal Cell Carcinoma in Adults
The clinical study will randomize up to 60 patients across 6 trial sites in the United States Toronto, Ontario--(Newsfile Corp. - August 27, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) ("Medicus" or the "Company") announces the enrollment of the first patient in its Phase 2 clinical trial SKNJCT-003 for the treatment of nodular basal cell carcinoma (nBCC).Clinical Trial Design The clinical study, SKNJCT-003, is designed to be a randomized, double-blind, placebo-controlled (P-MNA), multi-
- Newsfile
Medicus Pharma Ltd. Submits Updated Phase 2 Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin
THE FULL PACKAGE INCLUDES AN UPDATED INVESTIGATOR BROCHURE, CMC (CHEMISTRY, MANUFACTURING AND CONTROLS), STABILITY AND STERILTY DATA Toronto, Ontario--(Newsfile Corp. - July 15, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) ("Medicus" or the "Company") is pleased to announce the submission of an updated and complete Phase 2 Investigational New Drug (IND) clinical protocol (SKNJCT-003) to the United States Food and Drug Administration (FDA) to non-invasively treat basal cell carcinoma (BCC)
- Newsfile
Medicus Pharma Ltd. Announces Closing of Non-Brokered Private Placement of Common Shares and Conversion of Convertible Notes
Toronto, Ontario--(Newsfile Corp. - July 5, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce that it has completed its previously announced non-brokered private placement (the "Equity Offering") of 2,922,500 common shares of the Company ("Shares"), at an issuance price of US$2.00 per Share, for aggregate gross proceeds of US$5,845,000. The Company paid US$375,000 of finders' fees in connection with the Equity Offering.The Equity Offering closed into escr
